NF-B p65 pathway inhibition occurs through blocking phosphorylation at Ser536 and preventing nuclear translocation, suppressing transcription of pro-inflammatory genes
This combination is available in the Glow Stack, which combines all three peptides in a single lyophilized preparation
By activating GLP-1, GIP, and glucagon receptors, Retatrutide may help improve insulin sensitivity, support glucose control, and promote better overall energy balance
Furthermore, GLP-1 receptor agonists allow greater treatment customization based on individual patient's disease progression and therapeutic response
Adverse reactions to any substance can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk
A recent Phase 2 randomised placebo-controlled trial tested efinopegdutide in people with obesity over a 26-week period, where participants were randomly assigned weekly treatment with either placebo, 5 mg, 7.4 mg, 10 mg efinopegdutide, or 3 mg liraglutide daily